Close on Sep 18, 2026. Page updated Sep 19, 9:15 pm ET.
Boston Scientific closes at $43.34, down 0.5%, sitting below both its 50-day average of $46.83 and its 200-day average of $64.28, with the 50-day itself below the 200-day. The GekkoIndex reads 67.2, placing the stock in the Accumulation zone, while the price stands 35.9% below the Gekko Fair Value of $67.63.
This week's news centers on a downgrade and a product recall. Citi cut Boston Scientific to Neutral from Buy, lowering its price target to $50 from $57, citing an uncertain recovery path tied to competition in pulsed field ablation, a stagnating atrial appendage closure market, urology issues, and other setbacks in 2026. Separately, the company initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System over delayed atrial fibrillation Burden Alerts, with the FDA noted as taking enforcement interest. Other coverage referenced an earlier cyberattack disrupting manufacturing and shipping, expected to affect third-quarter and full-year 2026 guidance, along with commentary on acquisitions such as Penumbra and comparisons with Medtronic in electrophysiology.
The next earnings report is due 28 October 2026, 38 days out and beyond a typical 20-trading-day hold. Over the last 90 days, insiders made 5 open-market purchases and Congress recorded 2 buys with 0 sells; over the last 30 days, 2 unusual options signals appeared, with put premium of $6.9 million against call premium of $297,006. Seasonally, the next 20 trading days averaged -0.1% over 5 years, rising in 2 of them. Analyst consensus target stands at $62.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Boston Scientific scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
Below 50 and 200-day
Close $43.34 is below the 50-day ($46.83) and 200-day ($64.28) averages, and the 50-day is below the 200-day.
See the chart67.2, Accumulation
Reading 67.2 is in the Accumulation zone.
See the GekkoIndex35.9% below
Price is 35.9% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: 5 open-market insider purchases; Congress 2 buys / 0 sales. Last 30 days: 2 unusual options signals.
See smart moneyReports in 38 days
Next report Oct 28, 2026, 38 days away — outside a typical 20-trading-day hold.
See earnings−0.1% on average
From this point in the calendar, the next 20 trading days averaged −0.1% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Boston Scientific closed at $43.34 on Sep 18, 2026, −56.0% over the past year, inside a 52-week range of $42.20 to $105.65.
Use the left and right arrow keys to read daily values.
Put BSX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Boston Scientific designs, makes, and sells medical devices used across a range of interventional specialties. It is known for products that support the diagnosis and treatment of conditions affecting the heart, blood vessels, digestive and respiratory systems, urinary and pelvic health, the nervous system, and certain cancers, including catheters, stents, implantable cardiac devices, neurostimulation systems, and tools for cardiac mapping and imaging.
The company organizes its work into three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. MedSurg covers gastrointestinal, pulmonary, urological, and pelvic health tools. Rhythm and Neuro includes devices for cardiac rhythm management, cardiac mapping and ablation, and neurological treatments such as spinal cord stimulation and deep brain stimulation. Cardiovascular spans coronary stents, structural heart therapies, peripheral artery and vein treatments, and cancer-related products such as embolization devices and ablation systems.
Boston Scientific was founded in 1979 and is headquartered in Marlborough, Massachusetts. Its shares are listed on the NYSE under the ticker BSX.
Boston Scientific’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.2, in the Accumulation zone, down 1.5 points over five sessions.
Down 1.5 points over five sessions.
Reading for Sep 18, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 47 | +0.2% | −3.4% | ||
| Accumulation (current zone) | 197 | −0.6% | −2.4% | ||
| Neutral | 341 | −0.1% | +0.5% | ||
| Distribution | 73 | +0.6% | +1.6% | ||
| Selling | 4 | Too few readings yet | |||
Average BSX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Boston Scientific trades 35.9% below Gekko Fair Value of $67.63, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Boston Scientific shares are worth, recalculated every trading day.
$67.63
Gekko Fair Value, Sep 19, 2026
35.9% Undervalued
Insiders filed 5 open-market purchases in Boston Scientific worth $9.48M, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$9.48Min 5 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 26 | Morano Susan E director | Purchase | $100K |
| Aug 7 | David C Habiger Director | Purchase | $100K |
| Aug 5 | Michael F Mahoney Chairman, President & CEO | Purchase | $9.00M |
| Aug 5 | David C Habiger Director | Purchase | $50K |
| Aug 3 | Edward J Ludwig Director | Purchase | $227K |
From Form 4 filings, dated to when each was filed.
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 11 traded Aug 18 |
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Sep 7 traded Aug 10 |
From congressional disclosures, which report amounts as ranges.
Boston Scientific has been buying back its own shares.
From company filings.
2signals, 4% of the flagged premium in calls.
Latest: Bearish flow on Sep 4, $4.13M in unusual premium.
3of the funds Gekko tracks hold BSX.
Boston Scientific reports on Oct 28, 2026, before the open (38 days away), and beat the EPS estimate in 8 of its last 8 reports.
Oct 28, 2026
Expected before the open, 38 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | $0.86 est $0.83 | $5.44B est $5.38B | −0.1% |
| Apr 22, 2026 | $0.80 est $0.79 | $5.20B est $5.17B | +10.4% |
| Feb 4, 2026 | $0.80 est $0.78 | $5.29B est $5.28B | −15.3% |
| Oct 22, 2025 | $0.75 est $0.71 | $5.07B est $4.97B | +2.5% |
| Jul 23, 2025 | $0.75 est $0.73 | $5.06B est $4.89B | +3.0% |
| Apr 23, 2025 | $0.75 est $0.67 | $4.66B est $4.57B | +6.4% |
| Feb 5, 2025 | $0.70 est $0.66 | $4.56B est $4.42B | +1.4% |
| Oct 23, 2024 | $0.63 est $0.59 | $4.21B est $4.04B | −3.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Boston Scientific is $62.00, +43.1% from the last close, from 22 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 22 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Citi | $50 | +15.4% |
| Sep 17 | TD Cowen | $56 | +29.2% |
| Sep 17 | Citi | $50 | +15.4% |
| Sep 14 | Bank of America Securities | $54 | +24.6% |
| Sep 11 | Jefferies | $60 | +38.4% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Sep 19, Boston Scientific averaged −0.1% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.8% | 3 of 5 |
| Next 10 trading days | −1.4% | 1 of 5 |
| Next 15 trading days | −0.6% | 2 of 5 |
| Next 20 trading days | −0.1% | 2 of 5 |
| Next 30 trading days | +0.8% | 3 of 5 |
For scale, BSX’s typical 20-trading-day move in either direction is about 4.3%.
Boston Scientific’s market cap is $64.42B, with a P/E ratio of 17.8 and revenue of $21.00B over the last twelve months.
Coverage of Boston Scientific this week reads negative: 0 positive, 1 neutral and 6 negative headlines.
Boston Scientific’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
A peer links to its own page where one exists.
Boston Scientific’s market cap is $64.42B at the Sep 18, 2026 close of $43.34, with 1.45B shares outstanding. The shares trade on a P/E ratio of 17.8.
The consensus analyst 12-month price target for Boston Scientific is $62.00, +43.1% from the last close. Of the 22 firms that rated the stock in the last 90 days, 19 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Boston Scientific is undervalued: the Sep 18, 2026 close of $43.34 is 35.9% below Gekko Fair Value of $67.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Boston Scientific is expected to report on Oct 28, 2026, before the market opens (38 days away). Analysts expect earnings of $0.80 per share on revenue of $5.19B. Boston Scientific beat the earnings estimate in 8 of its last 8 reports, moving 5.3% on average across the report.
Boston Scientific’s 52-week high is $105.65 and its 52-week low is $42.20; it closed at $43.34 on Sep 18, 2026, −56.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 2 unusual options signals in Boston Scientific over the last 30 days, with $297K of flagged premium in calls and $6.95M in puts. The latest, bearish flow, was on Sep 4, 2026 with $4.13M in unusual premium. The signal-by-signal table is in Gekko.
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.